View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsRe:NewCell 将来の成長Future 基準チェック /26Re:NewCell利益と収益がそれぞれ年間82%と83%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に12.4% 82.7%なると予測されています。主要情報82.0%収益成長率82.73%EPS成長率Chemicals 収益成長8.9%収益成長率83.0%将来の株主資本利益率12.41%アナリストカバレッジLow最終更新日22 Dec 2023今後の成長に関する最新情報Breakeven Date Change • Nov 24Forecast to breakeven in 2025The 3 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 30% per year to 2024. The company is expected to make a profit of kr12.8m in 2025. Average annual earnings growth of 82% is required to achieve expected profit on schedule.Breakeven Date Change • Nov 24Forecast to breakeven in 2025The 3 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 30% per year to 2024. The company is expected to make a profit of kr12.8m in 2025. Average annual earnings growth of 82% is required to achieve expected profit on schedule.Price Target Changed • Nov 21Price target decreased by 51% to kr40.00Down from kr81.00, the current price target is an average from 2 analysts. New target price is 363% above last closing price of kr8.65. Stock is down 86% over the past year. The company is forecast to post a net loss per share of kr10.55 next year compared to a net loss per share of kr8.99 last year.Major Estimate Revision • Nov 14Consensus revenue estimates decrease by 16%, EPS upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from kr331.4m to kr276.8m. EPS estimate increased from -kr10.72 to -kr10.55 per share. Chemicals industry in Sweden expected to see average net income growth of 6.4% next year. Consensus price target down from kr81.00 to kr78.50. Share price fell 4.4% to kr9.57 over the past week.Major Estimate Revision • Oct 18Consensus EPS estimates fall by 20%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from kr361.1m to kr331.4m. Losses expected to increase from kr8.90 per share to kr10.72. Chemicals industry in Sweden expected to see average net income growth of 4.3% next year. Consensus price target down from kr166 to kr81.00. Share price fell 84% to kr8.52 over the past week.Breakeven Date Change • Oct 16Forecast breakeven date pushed back to 2025The 3 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 52% per year to 2024. The company is expected to make a profit of kr378.3m in 2025. Average annual earnings growth of 104% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesお知らせ • Jun 05Altor Equity Partners AB acquired Remaining Assets of Re:NewCell AB (publ) from Re:NewCell AB (publ).Altor Equity Partners AB acquired Remaining Assets of Re:NewCell AB (publ) from Re:NewCell AB (publ) on June 4, 2024.Altor Equity Partners AB completed the acquisition of Remaining Assets of Re:NewCell AB (publ) from Re:NewCell AB (publ) on June 4, 2024.お知らせ • Jan 10Re:NewCell AB Plans for Restructuring to Strengthen Organization Within Continuous Focus on SalesRe:NewCell AB announced that they are planning to start negotiations with the relevant trade unions regarding restructuring of the organization to improve efficiency while maintaining focus on sales. As part of the restructuring, the local authorities (Arbetsförmedlingen) will also be notified today. The planned restructuring will lead to a decrease in workforce of approximately 25%, just over 30 persons, and will also result in annual savings - reduction of personnel cost and other operating costs - of approximately 35 SEKm in total per annum when finalized.お知らせ • Dec 23+ 1 more updateRe:NewCell AB (publ) to Report Q3, 2024 Results on Nov 06, 2024Re:NewCell AB (publ) announced that they will report Q3, 2024 results on Nov 06, 2024New Risk • Dec 22New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: kr401m Forecast net loss in 2 years: kr27m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr578m free cash flow). Share price has been highly volatile over the past 3 months (33% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr27m net loss in 2 years). Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (kr353.3m market cap, or US$35.3m).お知らせ • Dec 13Peter Schulz Joins as Interim CFO at Re:NewCell AB (publ) Effective 1 January 2024Re:NewCell AB (publ) announced Peter Schulz will join the company in the role of interim Chief Financial Officer (CFO) from 1 January 2024. He comes from a role as CFO at Pacific Basin Shipping (publ.) in Hong Kong, a position he has held for the past six years. Peter Schulz has extensive experience as CFO from both listed and private companies for the last 10 years. Prior to that Peter Schulz spent more than 15 years, and held senior positions, in investment banking in Stockholm, London and Hong Kong, among others with Royal Bank of Canada and ABN Amro. With his extensive and broad experience, he will contribute well to the management team and the company.Breakeven Date Change • Nov 24Forecast to breakeven in 2025The 3 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 30% per year to 2024. The company is expected to make a profit of kr12.8m in 2025. Average annual earnings growth of 82% is required to achieve expected profit on schedule.Breakeven Date Change • Nov 24Forecast to breakeven in 2025The 3 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 30% per year to 2024. The company is expected to make a profit of kr12.8m in 2025. Average annual earnings growth of 82% is required to achieve expected profit on schedule.Price Target Changed • Nov 21Price target decreased by 51% to kr40.00Down from kr81.00, the current price target is an average from 2 analysts. New target price is 363% above last closing price of kr8.65. Stock is down 86% over the past year. The company is forecast to post a net loss per share of kr10.55 next year compared to a net loss per share of kr8.99 last year.Major Estimate Revision • Nov 14Consensus revenue estimates decrease by 16%, EPS upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from kr331.4m to kr276.8m. EPS estimate increased from -kr10.72 to -kr10.55 per share. Chemicals industry in Sweden expected to see average net income growth of 6.4% next year. Consensus price target down from kr81.00 to kr78.50. Share price fell 4.4% to kr9.57 over the past week.分析記事 • Nov 09Investors Give Re:NewCell AB (publ) (STO:RENEW) Shares A 84% HidingThe Re:NewCell AB (publ) ( STO:RENEW ) share price has fared very poorly over the last month, falling by a substantial...Reported Earnings • Nov 08Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2023 results: kr2.31 loss per share (improved from kr2.99 loss in 3Q 2022). Revenue: kr86.1m (up kr83.1m from 3Q 2022). Net loss: kr94.5m (loss narrowed 6.9% from 3Q 2022). Revenue missed analyst estimates by 12%. Earnings per share (EPS) exceeded analyst estimates by 11%. Revenue is forecast to grow 82% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Chemicals industry in Sweden.お知らせ • Nov 07Re:NewCell AB (publ) to Report Fiscal Year 2023 Final Results on Apr 26, 2024Re:NewCell AB (publ) announced that they will report fiscal year 2023 final results on Apr 26, 2024Major Estimate Revision • Oct 18Consensus EPS estimates fall by 20%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from kr361.1m to kr331.4m. Losses expected to increase from kr8.90 per share to kr10.72. Chemicals industry in Sweden expected to see average net income growth of 4.3% next year. Consensus price target down from kr166 to kr81.00. Share price fell 84% to kr8.52 over the past week.お知らせ • Oct 18Re:NewCell AB (publ) Announces CEO ChangesRe:NewCell AB (publ) announced that the Board has appointed Magnus Håkansson as the new acting CEO. Magnus has solid experience from leading roles in the retail and fashion sector and from leadership in a listed environment. He will start on October 16, 2023 and replaces Patrik Lundström, who has been the company's CEO since 2019. Magnus Håkansson was born in 1963, has a degree in economics from the Stockholm School of Economics and an MBA from MIT Sloan School of Management. He started his career as a management consultant at McKinsey and has since held several leading roles in global growth companies in the retail sector, as well as the pulp industry, including many years with experience from a listed environment. He most recently came from a role as CEO of MediaMarkt Sweden.Breakeven Date Change • Oct 16Forecast breakeven date pushed back to 2025The 3 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 52% per year to 2024. The company is expected to make a profit of kr378.3m in 2025. Average annual earnings growth of 104% is required to achieve expected profit on schedule.New Risk • Oct 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: kr566.9m (US$51.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr786m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Significant insider selling over the past 3 months (kr16m sold). Market cap is less than US$100m (kr566.9m market cap, or US$51.4m).お知らせ • Oct 13Re:Newcell AB (Publ) Provides Earnings Guidance for the Third Quarter of 2023Re:NewCell AB (publ) provided earnings guidance for the third quarter of 2023. For the quarter, the company expected to report Net loss of approximately SEK 105 million.Recent Insider Transactions • Oct 10CEO & MD recently sold kr3.5m worth of stockOn the 6th of October, Patrik Lundstrom sold around 109k shares on-market at roughly kr31.70 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth kr16m. Patrik has been a net seller over the last 12 months, reducing personal holdings by kr19m.New Risk • Oct 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr786m free cash flow). Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Shareholders have been diluted in the past year (22% increase in shares outstanding). Significant insider selling over the past 3 months (kr16m sold).Recent Insider Transactions Derivative • Sep 06CEO & MD exercised options to buy kr35m worth of stock.On the 31st of August, Patrik Lundstrom exercised options to buy 453k shares at a strike price of around kr48.43, costing a total of kr22m. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. Since December 2022, Patrik's direct individual holding has decreased from 814.21k shares to 452.30k. Company insiders have collectively bought kr32m more than they sold, via options and on-market transactions, in the last 12 months.Reported Earnings • Aug 30Second quarter 2023 earnings: EPS misses analyst expectationsSecond quarter 2023 results: kr2.82 loss per share (further deteriorated from kr2.09 loss in 2Q 2022). Revenue: kr86.0m (up kr83.5m from 2Q 2022). Net loss: kr105.4m (loss widened 54% from 2Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.3%. Revenue is forecast to grow 78% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Chemicals industry in Sweden.お知らせ • Aug 30+ 2 more updatesRe:NewCell AB (publ) to Report Q4, 2023 Results on Feb 13, 2024Re:NewCell AB (publ) announced that they will report Q4, 2023 results on Feb 13, 2024Breakeven Date Change • Aug 24Forecast breakeven date pushed back to 2025The 2 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr233.9m in 2025. Average annual earnings growth of 73% is required to achieve expected profit on schedule.Major Estimate Revision • Aug 23Consensus EPS estimates fall by 11%The consensus outlook for fiscal year 2023 has been updated. 2023 losses of -kr7.96 per share expected, vs -kr7.16 per share profit forecast previously. Revenue forecast reaffirmed at kr384.0m. Chemicals industry in Sweden expected to see average net income growth of 3.8% next year. Consensus price target of kr206 unchanged from last update. Share price rose 12% to kr76.55 over the past week.Recent Insider Transactions • Aug 01CEO & MD recently sold kr16m worth of stockOn the 27th of July, Patrik Lundstrom sold around 224k shares on-market at roughly kr71.36 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Patrik's only on-market trade for the last 12 months.お知らせ • Jul 17Re:NewCell AB (publ) Announces Toby Lawton to Leave His Position as CFORe:NewCell AB (publ) Toby Lawton, CFO at Renewcell AB (publ), has announced that he will leave his position for a similar position in another company. Toby will continue to work as CFO until a successor has been appointed or at the latest until the end of the year.Recent Insider Transactions Derivative • Jul 10CEO & MD exercised options to buy kr17m worth of stock.On the 6th of July, Patrik Lundstrom exercised options to buy 227k shares at a strike price of around kr48.43, costing a total of kr11m. This transaction amounted to 51% of their direct individual holding at the time of the trade. Since December 2022, Patrik's direct individual holding has decreased from 814.21k shares to 449.50k. Company insiders have collectively bought kr26m more than they sold, via options and on-market transactions, in the last 12 months.お知らせ • Jul 01Re:Newcell AB (Publ) Provides Production from Renewcell 1 Guidance in June 2023Re:NewCell AB (publ) provided production from Renewcell 1 guidance in June 2023. Production from Renewcell 1 is expected to reach 2,200-2,400 metric tons in June 2023, of which 2,100-2,300 metric tons are expected to be of prime quality and 2,200-2,400 metric tons are expected to be delivered to customers. The production in the month has been impacted by maintenance stops to upgrade and install new equipment in the shredding area.Major Estimate Revision • May 19Consensus revenue estimates fall by 20%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from kr437.9m to kr351.4m. Forecast losses increased from -kr6.42 to -kr7.58 per share. Chemicals industry in Sweden expected to see average net income growth of 1.2% next year. Consensus price target broadly unchanged at kr198. Share price fell 3.2% to kr79.00 over the past week.Major Estimate Revision • May 10Consensus revenue estimates increase by 23%The consensus outlook for revenues in fiscal year 2023 has improved. 2023 revenue forecast increased from kr356.3m to kr437.9m. Forecast losses expected to reduce from -kr6.70 to -kr6.42 per share. Chemicals industry in Sweden expected to see average net income decline 1.1% next year. Consensus price target of kr197 unchanged from last update. Share price was steady at kr81.25 over the past week.Reported Earnings • Apr 30Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: kr8.99 loss per share (further deteriorated from kr4.33 loss in FY 2021). Net loss: kr299.9m (loss widened 125% from FY 2021). Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) also surpassed analyst estimates by 3.0%. Revenue is forecast to grow 71% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Chemicals industry in Sweden.Major Estimate Revision • Apr 27Consensus EPS estimates fall by 11%The consensus outlook for fiscal year 2023 has been updated. 2023 losses of -kr6.70 per share expected, vs -kr6.02 per share profit forecast previously. Revenue forecast reaffirmed at kr370.2m. Chemicals industry in Sweden expected to see average net income decline 2.6% next year. Consensus price target down from kr220 to kr204. Share price rose 3.5% to kr76.10 over the past week.Price Target Changed • Apr 27Price target decreased by 7.6% to kr204Down from kr220, the current price target is an average from 3 analysts. New target price is 168% above last closing price of kr76.10. Stock is down 34% over the past year. The company is forecast to post a net loss per share of kr6.70 next year compared to a net loss per share of kr8.99 last year.Major Estimate Revision • Apr 25Consensus EPS estimates fall by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from kr370.2m to kr356.5m. Losses expected to increase from kr6.02 per share to kr6.70. Chemicals industry in Sweden expected to see average net income decline 2.9% next year. Consensus price target down from kr220 to kr204. Share price was steady at kr73.20 over the past week.Price Target Changed • Apr 24Price target decreased by 9.1% to kr204Down from kr224, the current price target is an average from 3 analysts. New target price is 180% above last closing price of kr72.70. Stock is down 42% over the past year. The company is forecast to post a net loss per share of kr6.02 next year compared to a net loss per share of kr8.99 last year.Major Estimate Revision • Apr 06Consensus revenue estimates fall by 16%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from kr439.1m to kr370.2m. Forecast losses increased from -kr4.96 to -kr6.02 per share. Chemicals industry in Sweden expected to see average net income decline 2.2% next year. Consensus price target broadly unchanged at kr220. Share price fell 6.8% to kr76.10 over the past week.お知らせ • Feb 16+ 1 more updateRe:NewCell AB (publ) to Report Q3, 2023 Results on Nov 07, 2023Re:NewCell AB (publ) announced that they will report Q3, 2023 results on Nov 07, 2023Breakeven Date Change • Feb 16Forecast to breakeven in 2024The 2 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr180.4m in 2024. Average annual earnings growth of 60% is required to achieve expected profit on schedule.Breakeven Date Change • Nov 29Forecast breakeven date pushed back to 2024The 2 analysts covering Re:NewCell previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 22% per year to 2023. The company is expected to make a profit of kr118.9m in 2024. Average annual earnings growth of 72% is required to achieve expected profit on schedule.Board Change • Nov 16High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Director Om Bhatia is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Breakeven Date Change • Oct 29Forecast breakeven date pushed back to 2024The 2 analysts covering Re:NewCell previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 65% per year to 2023. The company is expected to make a profit of kr122.1m in 2024. Average annual earnings growth of 75% is required to achieve expected profit on schedule.Reported Earnings • Oct 28Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: kr2.99 loss per share (further deteriorated from kr0.80 loss in 3Q 2021). Net loss: kr101.5m (loss widened 314% from 3Q 2021). Revenue missed analyst estimates by 91%. Earnings per share (EPS) also missed analyst estimates by 116%. Revenue is forecast to grow 82% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Chemicals industry in Sweden.お知らせ • Oct 28+ 1 more updateRe:NewCell AB (publ) to Report Q2, 2023 Results on Aug 18, 2023Re:NewCell AB (publ) announced that they will report Q2, 2023 results on Aug 18, 2023Major Estimate Revision • Sep 02Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 losses of -kr8.34 per share expected, vs -kr6.87 per share profit forecast previously. Revenue forecast reaffirmed at kr133.9m. Chemicals industry in Sweden expected to see average net income growth of 6.7% next year. Consensus price target of kr275 unchanged from last update. Share price fell 6.2% to kr87.25 over the past week.Reported Earnings • Aug 26Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2022 results: kr2.09 loss per share (down from kr0.76 loss in 2Q 2021). Net loss: kr68.4m (loss widened 192% from 2Q 2021). Revenue missed analyst estimates by 19%. Earnings per share (EPS) exceeded analyst estimates by 100%. Over the next year, revenue is forecast to grow 3,859%, compared to a 501% growth forecast for the Chemicals industry in Sweden.Board Change • Jun 02High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Director Om Bhatia is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Recent Insider Transactions • May 24Chief Financial Officer recently bought kr116k worth of stockOn the 18th of May, Hugo Petit bought around 1k shares on-market at roughly kr116 per share. This was the largest purchase by an insider in the last 3 months. Hugo has been a buyer over the last 12 months, purchasing a net total of kr479k worth in shares.Major Estimate Revision • May 11Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 expected loss increased from -kr5.23 to -kr6.95 per share. Revenue forecast of kr126.2m unchanged since last update. Chemicals industry in Sweden expected to see average net income growth of 8.9% next year. Consensus price target down from kr370 to kr300. Share price was steady at kr111 over the past week.Reported Earnings • May 05First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2022 results: kr1.75 loss per share (down from kr0.63 loss in 1Q 2021). Net loss: kr54.0m (loss widened 181% from 1Q 2021). Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) missed analyst estimates by 132%. Over the next year, revenue is forecast to grow 4,106%, compared to a 422% growth forecast for the industry in Sweden.お知らせ • May 05Re:NewCell AB (publ) to Report Q1, 2023 Results on May 03, 2023Re:NewCell AB (publ) announced that they will report Q1, 2023 results on May 03, 2023Price Target Changed • Apr 27Price target increased to kr370Up from kr338, the current price target is an average from 2 analysts. New target price is 212% above last closing price of kr119. Stock is down 55% over the past year. The company is forecast to post a net loss per share of kr5.23 next year compared to a net loss per share of kr4.33 last year.Board Change • Apr 27High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Director Om Bhatia is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Price Target Changed • Apr 06Price target increased to kr370Up from kr338, the current price target is an average from 2 analysts. New target price is 190% above last closing price of kr128. Stock is down 47% over the past year. The company is forecast to post a net loss per share of kr5.23 next year compared to a net loss per share of kr4.33 last year.Breakeven Date Change • Mar 09Forecast breakeven date moved forward to 2023The 2 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr37.9m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Recent Insider Transactions • Mar 03Chief Growth Officer recently sold kr65k worth of stockOn the 28th of February, Harald Cavalli-Bjorkman sold around 500 shares on-market at roughly kr129 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought kr1.6m more than they sold in the last 12 months.Major Estimate Revision • Feb 23Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 losses of -kr5.99 per share expected, vs -kr4.12 per share profit forecast previously. Revenue forecast reaffirmed at kr126.2m. Chemicals industry in Sweden expected to see average net income growth of 15% next year. Consensus price target of kr343 unchanged from last update. Share price fell 22% to kr126 over the past week.Breakeven Date Change • Feb 19Forecast breakeven date moved forward to 2023The 2 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr37.9m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Reported Earnings • Feb 17Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: kr4.33 loss per share (down from kr3.34 loss in FY 2020). Net loss: kr133.4m (loss widened 94% from FY 2020). Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) also surpassed analyst estimates by 32%. Over the next year, revenue is forecast to grow 1,979%, compared to a 572% growth forecast for the industry in Sweden.お知らせ • Feb 17Re:NewCell AB (publ) to Report Q4, 2022 Results on Feb 15, 2023Re:NewCell AB (publ) announced that they will report Q4, 2022 results on Feb 15, 2023Recent Insider Transactions Derivative • Feb 03Chief Growth Officer exercised options to buy kr1.1m worth of stock.On the 1st of February, Harald Cavalli-Bjorkman exercised options to buy 6k shares at a strike price of around kr13.54, costing a total of kr79k. This transaction amounted to 48% of their direct individual holding at the time of the trade. Since June 2021, Harald has owned 12.09k shares directly. Company insiders have collectively bought kr2.4m more than they sold, via options and on-market transactions, in the last 12 months.Breakeven Date Change • Jan 26Forecast to breakeven in 2024The 2 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr5.77m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Major Estimate Revision • Jan 22Consensus revenue estimates increase by 67%The consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from kr5.51m to kr9.18m. Forecast losses expected to reduce from -kr3.26 to -kr3.06 per share. Chemicals industry in Sweden expected to see average net income growth of 15% next year. Consensus price target of kr343 unchanged from last update. Share price fell 3.1% to kr175 over the past week.Recent Insider Transactions • Jan 14Chief Financial Officer recently bought kr80k worth of stockOn the 12th of January, Hugo Petit bought around 425 shares on-market at roughly kr187 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr100k. Hugo has been a buyer over the last 12 months, purchasing a net total of kr319k worth in shares.Breakeven Date Change • Jan 07Forecast to breakeven in 2024The 2 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr5.77m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 2 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr5.77m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Major Estimate Revision • Dec 21Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from kr9.18m to kr6.00m. EPS estimate increased from -kr3.49 to -kr3.26 per share. Chemicals industry in Sweden expected to see average net income growth of 16% next year. Consensus price target of kr343 unchanged from last update. Share price fell 6.5% to kr214 over the past week.Recent Insider Transactions • Dec 18Chief Executive Officer recently bought kr100k worth of stockOn the 14th of December, Patrik Lundstrom bought around 450 shares on-market at roughly kr221 per share. This was the largest purchase by an insider in the last 3 months. Patrik has been a buyer over the last 12 months, purchasing a net total of kr613k worth in shares.Recent Insider Transactions Derivative • Nov 25Plant Manager Ortviken exercised options to buy kr10m worth of stock.On the 22nd of November, Henrik Dahlbom exercised options to buy 41k shares at a strike price of around kr17.08, costing a total of kr701k. This transaction amounted to 5,861% of their direct individual holding at the time of the trade. Since June 2021, Henrik has owned 700.00 shares directly. Company insiders have collectively bought kr2.2m more than they sold, via options and on-market transactions, in the last 12 months.Reported Earnings • Nov 07Third quarter 2021 earnings released: kr0.80 loss per share (vs kr0.81 loss in 3Q 2020)Third quarter 2021 results: Net loss: kr24.5m (loss widened 55% from 3Q 2020).Major Estimate Revision • Jul 09Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 losses forecast to reduce from -kr3.49 per share to -kr3.06 per share. Revenue forecast reaffirmed at kr9.18m. Chemicals industry in Sweden expected to see average net income growth of 25% next year. Consensus price target of kr343 unchanged from last update. Share price rose 4.8% to kr187 over the past week.Recent Insider Transactions • Jun 24Plant Manager Ortviken recently bought kr108k worth of stockOn the 21st of June, Henrik Dahlbom bought around 700 shares on-market at roughly kr155 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr513k. Insiders have collectively bought kr1.5m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Jun 13Chief Executive Officer recently bought kr513k worth of stockOn the 11th of June, Patrik Lundstrom bought around 3k shares on-market at roughly kr183 per share. This was the largest purchase by an insider in the last 3 months. This was Patrik's only on-market trade for the last 12 months.Recent Insider Transactions • May 26Chief Financial Officer recently bought kr55k worth of stockOn the 19th of May, Hugo Petit bought around 240 shares on-market at roughly kr228 per share. This was the largest purchase by an insider in the last 3 months. This was Hugo's only on-market trade for the last 12 months.Executive Departure • May 22Director has left the companyOn the 19th of May, Erik Karlsson's tenure in the role of Director ended. We don't have any record of a personal shareholding under Erik's name. A total of 3 executives have left over the last 12 months.Executive Departure • May 22Director has left the companyOn the 19th of May, Henrik Norlin's tenure in the role of Director ended. We don't have any record of a personal shareholding under Henrik's name. A total of 3 executives have left over the last 12 months.Recent Insider Transactions • May 21Interim Chief Financial Officer recently bought kr55k worth of stockOn the 19th of May, Hugo Petit bought around 240 shares on-market at roughly kr228 per share. This was the largest purchase by an insider in the last 3 months. This was Hugo's only on-market trade for the last 12 months.業績と収益の成長予測OM:RENEW - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20251,39813N/AN/A312/31/2024682-145N/AN/A312/31/2023260-445N/AN/A39/30/2023205-401-578-342N/A6/30/2023124-408-786-355N/A3/31/202341-371-1,150-398N/A12/31/202214-300-1,278-398N/A9/30/20229-290-1,139-329N/A6/30/20226-213-1,006-263N/A3/31/20224-168-645-196N/A12/31/20214-133-430-118N/A9/30/20212-88-329-78N/A6/30/20211-80-181-60N/A3/31/20212-72-146-66N/A12/31/20201-69-85-52N/A9/30/20202-60-51-50N/A12/31/20191-38-32-31N/A12/31/2018N/A-18-30-19N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: RENEW今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: RENEW今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: RENEW今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: RENEWの収益 ( 83% ) Swedish市場 ( 0.02% ) よりも速いペースで成長すると予測されています。高い収益成長: RENEWの収益 ( 83% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: RENEWの 自己資本利益率 は、3年後には低くなると予測されています ( 12.4 %)。成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/02/29 13:23終値2024/02/29 00:00収益2023/09/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Re:NewCell AB (publ) 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Daniel OvinNordea MarketsJohan SpetzPareto Securities
Breakeven Date Change • Nov 24Forecast to breakeven in 2025The 3 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 30% per year to 2024. The company is expected to make a profit of kr12.8m in 2025. Average annual earnings growth of 82% is required to achieve expected profit on schedule.
Breakeven Date Change • Nov 24Forecast to breakeven in 2025The 3 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 30% per year to 2024. The company is expected to make a profit of kr12.8m in 2025. Average annual earnings growth of 82% is required to achieve expected profit on schedule.
Price Target Changed • Nov 21Price target decreased by 51% to kr40.00Down from kr81.00, the current price target is an average from 2 analysts. New target price is 363% above last closing price of kr8.65. Stock is down 86% over the past year. The company is forecast to post a net loss per share of kr10.55 next year compared to a net loss per share of kr8.99 last year.
Major Estimate Revision • Nov 14Consensus revenue estimates decrease by 16%, EPS upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from kr331.4m to kr276.8m. EPS estimate increased from -kr10.72 to -kr10.55 per share. Chemicals industry in Sweden expected to see average net income growth of 6.4% next year. Consensus price target down from kr81.00 to kr78.50. Share price fell 4.4% to kr9.57 over the past week.
Major Estimate Revision • Oct 18Consensus EPS estimates fall by 20%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from kr361.1m to kr331.4m. Losses expected to increase from kr8.90 per share to kr10.72. Chemicals industry in Sweden expected to see average net income growth of 4.3% next year. Consensus price target down from kr166 to kr81.00. Share price fell 84% to kr8.52 over the past week.
Breakeven Date Change • Oct 16Forecast breakeven date pushed back to 2025The 3 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 52% per year to 2024. The company is expected to make a profit of kr378.3m in 2025. Average annual earnings growth of 104% is required to achieve expected profit on schedule.
お知らせ • Jun 05Altor Equity Partners AB acquired Remaining Assets of Re:NewCell AB (publ) from Re:NewCell AB (publ).Altor Equity Partners AB acquired Remaining Assets of Re:NewCell AB (publ) from Re:NewCell AB (publ) on June 4, 2024.Altor Equity Partners AB completed the acquisition of Remaining Assets of Re:NewCell AB (publ) from Re:NewCell AB (publ) on June 4, 2024.
お知らせ • Jan 10Re:NewCell AB Plans for Restructuring to Strengthen Organization Within Continuous Focus on SalesRe:NewCell AB announced that they are planning to start negotiations with the relevant trade unions regarding restructuring of the organization to improve efficiency while maintaining focus on sales. As part of the restructuring, the local authorities (Arbetsförmedlingen) will also be notified today. The planned restructuring will lead to a decrease in workforce of approximately 25%, just over 30 persons, and will also result in annual savings - reduction of personnel cost and other operating costs - of approximately 35 SEKm in total per annum when finalized.
お知らせ • Dec 23+ 1 more updateRe:NewCell AB (publ) to Report Q3, 2024 Results on Nov 06, 2024Re:NewCell AB (publ) announced that they will report Q3, 2024 results on Nov 06, 2024
New Risk • Dec 22New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: kr401m Forecast net loss in 2 years: kr27m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr578m free cash flow). Share price has been highly volatile over the past 3 months (33% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr27m net loss in 2 years). Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (kr353.3m market cap, or US$35.3m).
お知らせ • Dec 13Peter Schulz Joins as Interim CFO at Re:NewCell AB (publ) Effective 1 January 2024Re:NewCell AB (publ) announced Peter Schulz will join the company in the role of interim Chief Financial Officer (CFO) from 1 January 2024. He comes from a role as CFO at Pacific Basin Shipping (publ.) in Hong Kong, a position he has held for the past six years. Peter Schulz has extensive experience as CFO from both listed and private companies for the last 10 years. Prior to that Peter Schulz spent more than 15 years, and held senior positions, in investment banking in Stockholm, London and Hong Kong, among others with Royal Bank of Canada and ABN Amro. With his extensive and broad experience, he will contribute well to the management team and the company.
Breakeven Date Change • Nov 24Forecast to breakeven in 2025The 3 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 30% per year to 2024. The company is expected to make a profit of kr12.8m in 2025. Average annual earnings growth of 82% is required to achieve expected profit on schedule.
Breakeven Date Change • Nov 24Forecast to breakeven in 2025The 3 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 30% per year to 2024. The company is expected to make a profit of kr12.8m in 2025. Average annual earnings growth of 82% is required to achieve expected profit on schedule.
Price Target Changed • Nov 21Price target decreased by 51% to kr40.00Down from kr81.00, the current price target is an average from 2 analysts. New target price is 363% above last closing price of kr8.65. Stock is down 86% over the past year. The company is forecast to post a net loss per share of kr10.55 next year compared to a net loss per share of kr8.99 last year.
Major Estimate Revision • Nov 14Consensus revenue estimates decrease by 16%, EPS upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from kr331.4m to kr276.8m. EPS estimate increased from -kr10.72 to -kr10.55 per share. Chemicals industry in Sweden expected to see average net income growth of 6.4% next year. Consensus price target down from kr81.00 to kr78.50. Share price fell 4.4% to kr9.57 over the past week.
分析記事 • Nov 09Investors Give Re:NewCell AB (publ) (STO:RENEW) Shares A 84% HidingThe Re:NewCell AB (publ) ( STO:RENEW ) share price has fared very poorly over the last month, falling by a substantial...
Reported Earnings • Nov 08Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2023 results: kr2.31 loss per share (improved from kr2.99 loss in 3Q 2022). Revenue: kr86.1m (up kr83.1m from 3Q 2022). Net loss: kr94.5m (loss narrowed 6.9% from 3Q 2022). Revenue missed analyst estimates by 12%. Earnings per share (EPS) exceeded analyst estimates by 11%. Revenue is forecast to grow 82% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Chemicals industry in Sweden.
お知らせ • Nov 07Re:NewCell AB (publ) to Report Fiscal Year 2023 Final Results on Apr 26, 2024Re:NewCell AB (publ) announced that they will report fiscal year 2023 final results on Apr 26, 2024
Major Estimate Revision • Oct 18Consensus EPS estimates fall by 20%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from kr361.1m to kr331.4m. Losses expected to increase from kr8.90 per share to kr10.72. Chemicals industry in Sweden expected to see average net income growth of 4.3% next year. Consensus price target down from kr166 to kr81.00. Share price fell 84% to kr8.52 over the past week.
お知らせ • Oct 18Re:NewCell AB (publ) Announces CEO ChangesRe:NewCell AB (publ) announced that the Board has appointed Magnus Håkansson as the new acting CEO. Magnus has solid experience from leading roles in the retail and fashion sector and from leadership in a listed environment. He will start on October 16, 2023 and replaces Patrik Lundström, who has been the company's CEO since 2019. Magnus Håkansson was born in 1963, has a degree in economics from the Stockholm School of Economics and an MBA from MIT Sloan School of Management. He started his career as a management consultant at McKinsey and has since held several leading roles in global growth companies in the retail sector, as well as the pulp industry, including many years with experience from a listed environment. He most recently came from a role as CEO of MediaMarkt Sweden.
Breakeven Date Change • Oct 16Forecast breakeven date pushed back to 2025The 3 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 52% per year to 2024. The company is expected to make a profit of kr378.3m in 2025. Average annual earnings growth of 104% is required to achieve expected profit on schedule.
New Risk • Oct 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: kr566.9m (US$51.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr786m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Significant insider selling over the past 3 months (kr16m sold). Market cap is less than US$100m (kr566.9m market cap, or US$51.4m).
お知らせ • Oct 13Re:Newcell AB (Publ) Provides Earnings Guidance for the Third Quarter of 2023Re:NewCell AB (publ) provided earnings guidance for the third quarter of 2023. For the quarter, the company expected to report Net loss of approximately SEK 105 million.
Recent Insider Transactions • Oct 10CEO & MD recently sold kr3.5m worth of stockOn the 6th of October, Patrik Lundstrom sold around 109k shares on-market at roughly kr31.70 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth kr16m. Patrik has been a net seller over the last 12 months, reducing personal holdings by kr19m.
New Risk • Oct 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr786m free cash flow). Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Shareholders have been diluted in the past year (22% increase in shares outstanding). Significant insider selling over the past 3 months (kr16m sold).
Recent Insider Transactions Derivative • Sep 06CEO & MD exercised options to buy kr35m worth of stock.On the 31st of August, Patrik Lundstrom exercised options to buy 453k shares at a strike price of around kr48.43, costing a total of kr22m. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. Since December 2022, Patrik's direct individual holding has decreased from 814.21k shares to 452.30k. Company insiders have collectively bought kr32m more than they sold, via options and on-market transactions, in the last 12 months.
Reported Earnings • Aug 30Second quarter 2023 earnings: EPS misses analyst expectationsSecond quarter 2023 results: kr2.82 loss per share (further deteriorated from kr2.09 loss in 2Q 2022). Revenue: kr86.0m (up kr83.5m from 2Q 2022). Net loss: kr105.4m (loss widened 54% from 2Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.3%. Revenue is forecast to grow 78% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Chemicals industry in Sweden.
お知らせ • Aug 30+ 2 more updatesRe:NewCell AB (publ) to Report Q4, 2023 Results on Feb 13, 2024Re:NewCell AB (publ) announced that they will report Q4, 2023 results on Feb 13, 2024
Breakeven Date Change • Aug 24Forecast breakeven date pushed back to 2025The 2 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr233.9m in 2025. Average annual earnings growth of 73% is required to achieve expected profit on schedule.
Major Estimate Revision • Aug 23Consensus EPS estimates fall by 11%The consensus outlook for fiscal year 2023 has been updated. 2023 losses of -kr7.96 per share expected, vs -kr7.16 per share profit forecast previously. Revenue forecast reaffirmed at kr384.0m. Chemicals industry in Sweden expected to see average net income growth of 3.8% next year. Consensus price target of kr206 unchanged from last update. Share price rose 12% to kr76.55 over the past week.
Recent Insider Transactions • Aug 01CEO & MD recently sold kr16m worth of stockOn the 27th of July, Patrik Lundstrom sold around 224k shares on-market at roughly kr71.36 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Patrik's only on-market trade for the last 12 months.
お知らせ • Jul 17Re:NewCell AB (publ) Announces Toby Lawton to Leave His Position as CFORe:NewCell AB (publ) Toby Lawton, CFO at Renewcell AB (publ), has announced that he will leave his position for a similar position in another company. Toby will continue to work as CFO until a successor has been appointed or at the latest until the end of the year.
Recent Insider Transactions Derivative • Jul 10CEO & MD exercised options to buy kr17m worth of stock.On the 6th of July, Patrik Lundstrom exercised options to buy 227k shares at a strike price of around kr48.43, costing a total of kr11m. This transaction amounted to 51% of their direct individual holding at the time of the trade. Since December 2022, Patrik's direct individual holding has decreased from 814.21k shares to 449.50k. Company insiders have collectively bought kr26m more than they sold, via options and on-market transactions, in the last 12 months.
お知らせ • Jul 01Re:Newcell AB (Publ) Provides Production from Renewcell 1 Guidance in June 2023Re:NewCell AB (publ) provided production from Renewcell 1 guidance in June 2023. Production from Renewcell 1 is expected to reach 2,200-2,400 metric tons in June 2023, of which 2,100-2,300 metric tons are expected to be of prime quality and 2,200-2,400 metric tons are expected to be delivered to customers. The production in the month has been impacted by maintenance stops to upgrade and install new equipment in the shredding area.
Major Estimate Revision • May 19Consensus revenue estimates fall by 20%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from kr437.9m to kr351.4m. Forecast losses increased from -kr6.42 to -kr7.58 per share. Chemicals industry in Sweden expected to see average net income growth of 1.2% next year. Consensus price target broadly unchanged at kr198. Share price fell 3.2% to kr79.00 over the past week.
Major Estimate Revision • May 10Consensus revenue estimates increase by 23%The consensus outlook for revenues in fiscal year 2023 has improved. 2023 revenue forecast increased from kr356.3m to kr437.9m. Forecast losses expected to reduce from -kr6.70 to -kr6.42 per share. Chemicals industry in Sweden expected to see average net income decline 1.1% next year. Consensus price target of kr197 unchanged from last update. Share price was steady at kr81.25 over the past week.
Reported Earnings • Apr 30Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: kr8.99 loss per share (further deteriorated from kr4.33 loss in FY 2021). Net loss: kr299.9m (loss widened 125% from FY 2021). Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) also surpassed analyst estimates by 3.0%. Revenue is forecast to grow 71% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Chemicals industry in Sweden.
Major Estimate Revision • Apr 27Consensus EPS estimates fall by 11%The consensus outlook for fiscal year 2023 has been updated. 2023 losses of -kr6.70 per share expected, vs -kr6.02 per share profit forecast previously. Revenue forecast reaffirmed at kr370.2m. Chemicals industry in Sweden expected to see average net income decline 2.6% next year. Consensus price target down from kr220 to kr204. Share price rose 3.5% to kr76.10 over the past week.
Price Target Changed • Apr 27Price target decreased by 7.6% to kr204Down from kr220, the current price target is an average from 3 analysts. New target price is 168% above last closing price of kr76.10. Stock is down 34% over the past year. The company is forecast to post a net loss per share of kr6.70 next year compared to a net loss per share of kr8.99 last year.
Major Estimate Revision • Apr 25Consensus EPS estimates fall by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from kr370.2m to kr356.5m. Losses expected to increase from kr6.02 per share to kr6.70. Chemicals industry in Sweden expected to see average net income decline 2.9% next year. Consensus price target down from kr220 to kr204. Share price was steady at kr73.20 over the past week.
Price Target Changed • Apr 24Price target decreased by 9.1% to kr204Down from kr224, the current price target is an average from 3 analysts. New target price is 180% above last closing price of kr72.70. Stock is down 42% over the past year. The company is forecast to post a net loss per share of kr6.02 next year compared to a net loss per share of kr8.99 last year.
Major Estimate Revision • Apr 06Consensus revenue estimates fall by 16%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from kr439.1m to kr370.2m. Forecast losses increased from -kr4.96 to -kr6.02 per share. Chemicals industry in Sweden expected to see average net income decline 2.2% next year. Consensus price target broadly unchanged at kr220. Share price fell 6.8% to kr76.10 over the past week.
お知らせ • Feb 16+ 1 more updateRe:NewCell AB (publ) to Report Q3, 2023 Results on Nov 07, 2023Re:NewCell AB (publ) announced that they will report Q3, 2023 results on Nov 07, 2023
Breakeven Date Change • Feb 16Forecast to breakeven in 2024The 2 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr180.4m in 2024. Average annual earnings growth of 60% is required to achieve expected profit on schedule.
Breakeven Date Change • Nov 29Forecast breakeven date pushed back to 2024The 2 analysts covering Re:NewCell previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 22% per year to 2023. The company is expected to make a profit of kr118.9m in 2024. Average annual earnings growth of 72% is required to achieve expected profit on schedule.
Board Change • Nov 16High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Director Om Bhatia is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Breakeven Date Change • Oct 29Forecast breakeven date pushed back to 2024The 2 analysts covering Re:NewCell previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 65% per year to 2023. The company is expected to make a profit of kr122.1m in 2024. Average annual earnings growth of 75% is required to achieve expected profit on schedule.
Reported Earnings • Oct 28Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: kr2.99 loss per share (further deteriorated from kr0.80 loss in 3Q 2021). Net loss: kr101.5m (loss widened 314% from 3Q 2021). Revenue missed analyst estimates by 91%. Earnings per share (EPS) also missed analyst estimates by 116%. Revenue is forecast to grow 82% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Chemicals industry in Sweden.
お知らせ • Oct 28+ 1 more updateRe:NewCell AB (publ) to Report Q2, 2023 Results on Aug 18, 2023Re:NewCell AB (publ) announced that they will report Q2, 2023 results on Aug 18, 2023
Major Estimate Revision • Sep 02Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 losses of -kr8.34 per share expected, vs -kr6.87 per share profit forecast previously. Revenue forecast reaffirmed at kr133.9m. Chemicals industry in Sweden expected to see average net income growth of 6.7% next year. Consensus price target of kr275 unchanged from last update. Share price fell 6.2% to kr87.25 over the past week.
Reported Earnings • Aug 26Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2022 results: kr2.09 loss per share (down from kr0.76 loss in 2Q 2021). Net loss: kr68.4m (loss widened 192% from 2Q 2021). Revenue missed analyst estimates by 19%. Earnings per share (EPS) exceeded analyst estimates by 100%. Over the next year, revenue is forecast to grow 3,859%, compared to a 501% growth forecast for the Chemicals industry in Sweden.
Board Change • Jun 02High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Director Om Bhatia is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Recent Insider Transactions • May 24Chief Financial Officer recently bought kr116k worth of stockOn the 18th of May, Hugo Petit bought around 1k shares on-market at roughly kr116 per share. This was the largest purchase by an insider in the last 3 months. Hugo has been a buyer over the last 12 months, purchasing a net total of kr479k worth in shares.
Major Estimate Revision • May 11Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 expected loss increased from -kr5.23 to -kr6.95 per share. Revenue forecast of kr126.2m unchanged since last update. Chemicals industry in Sweden expected to see average net income growth of 8.9% next year. Consensus price target down from kr370 to kr300. Share price was steady at kr111 over the past week.
Reported Earnings • May 05First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2022 results: kr1.75 loss per share (down from kr0.63 loss in 1Q 2021). Net loss: kr54.0m (loss widened 181% from 1Q 2021). Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) missed analyst estimates by 132%. Over the next year, revenue is forecast to grow 4,106%, compared to a 422% growth forecast for the industry in Sweden.
お知らせ • May 05Re:NewCell AB (publ) to Report Q1, 2023 Results on May 03, 2023Re:NewCell AB (publ) announced that they will report Q1, 2023 results on May 03, 2023
Price Target Changed • Apr 27Price target increased to kr370Up from kr338, the current price target is an average from 2 analysts. New target price is 212% above last closing price of kr119. Stock is down 55% over the past year. The company is forecast to post a net loss per share of kr5.23 next year compared to a net loss per share of kr4.33 last year.
Board Change • Apr 27High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Director Om Bhatia is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Price Target Changed • Apr 06Price target increased to kr370Up from kr338, the current price target is an average from 2 analysts. New target price is 190% above last closing price of kr128. Stock is down 47% over the past year. The company is forecast to post a net loss per share of kr5.23 next year compared to a net loss per share of kr4.33 last year.
Breakeven Date Change • Mar 09Forecast breakeven date moved forward to 2023The 2 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr37.9m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Recent Insider Transactions • Mar 03Chief Growth Officer recently sold kr65k worth of stockOn the 28th of February, Harald Cavalli-Bjorkman sold around 500 shares on-market at roughly kr129 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought kr1.6m more than they sold in the last 12 months.
Major Estimate Revision • Feb 23Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 losses of -kr5.99 per share expected, vs -kr4.12 per share profit forecast previously. Revenue forecast reaffirmed at kr126.2m. Chemicals industry in Sweden expected to see average net income growth of 15% next year. Consensus price target of kr343 unchanged from last update. Share price fell 22% to kr126 over the past week.
Breakeven Date Change • Feb 19Forecast breakeven date moved forward to 2023The 2 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr37.9m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Reported Earnings • Feb 17Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: kr4.33 loss per share (down from kr3.34 loss in FY 2020). Net loss: kr133.4m (loss widened 94% from FY 2020). Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) also surpassed analyst estimates by 32%. Over the next year, revenue is forecast to grow 1,979%, compared to a 572% growth forecast for the industry in Sweden.
お知らせ • Feb 17Re:NewCell AB (publ) to Report Q4, 2022 Results on Feb 15, 2023Re:NewCell AB (publ) announced that they will report Q4, 2022 results on Feb 15, 2023
Recent Insider Transactions Derivative • Feb 03Chief Growth Officer exercised options to buy kr1.1m worth of stock.On the 1st of February, Harald Cavalli-Bjorkman exercised options to buy 6k shares at a strike price of around kr13.54, costing a total of kr79k. This transaction amounted to 48% of their direct individual holding at the time of the trade. Since June 2021, Harald has owned 12.09k shares directly. Company insiders have collectively bought kr2.4m more than they sold, via options and on-market transactions, in the last 12 months.
Breakeven Date Change • Jan 26Forecast to breakeven in 2024The 2 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr5.77m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Major Estimate Revision • Jan 22Consensus revenue estimates increase by 67%The consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from kr5.51m to kr9.18m. Forecast losses expected to reduce from -kr3.26 to -kr3.06 per share. Chemicals industry in Sweden expected to see average net income growth of 15% next year. Consensus price target of kr343 unchanged from last update. Share price fell 3.1% to kr175 over the past week.
Recent Insider Transactions • Jan 14Chief Financial Officer recently bought kr80k worth of stockOn the 12th of January, Hugo Petit bought around 425 shares on-market at roughly kr187 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr100k. Hugo has been a buyer over the last 12 months, purchasing a net total of kr319k worth in shares.
Breakeven Date Change • Jan 07Forecast to breakeven in 2024The 2 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr5.77m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 2 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr5.77m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Major Estimate Revision • Dec 21Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from kr9.18m to kr6.00m. EPS estimate increased from -kr3.49 to -kr3.26 per share. Chemicals industry in Sweden expected to see average net income growth of 16% next year. Consensus price target of kr343 unchanged from last update. Share price fell 6.5% to kr214 over the past week.
Recent Insider Transactions • Dec 18Chief Executive Officer recently bought kr100k worth of stockOn the 14th of December, Patrik Lundstrom bought around 450 shares on-market at roughly kr221 per share. This was the largest purchase by an insider in the last 3 months. Patrik has been a buyer over the last 12 months, purchasing a net total of kr613k worth in shares.
Recent Insider Transactions Derivative • Nov 25Plant Manager Ortviken exercised options to buy kr10m worth of stock.On the 22nd of November, Henrik Dahlbom exercised options to buy 41k shares at a strike price of around kr17.08, costing a total of kr701k. This transaction amounted to 5,861% of their direct individual holding at the time of the trade. Since June 2021, Henrik has owned 700.00 shares directly. Company insiders have collectively bought kr2.2m more than they sold, via options and on-market transactions, in the last 12 months.
Reported Earnings • Nov 07Third quarter 2021 earnings released: kr0.80 loss per share (vs kr0.81 loss in 3Q 2020)Third quarter 2021 results: Net loss: kr24.5m (loss widened 55% from 3Q 2020).
Major Estimate Revision • Jul 09Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 losses forecast to reduce from -kr3.49 per share to -kr3.06 per share. Revenue forecast reaffirmed at kr9.18m. Chemicals industry in Sweden expected to see average net income growth of 25% next year. Consensus price target of kr343 unchanged from last update. Share price rose 4.8% to kr187 over the past week.
Recent Insider Transactions • Jun 24Plant Manager Ortviken recently bought kr108k worth of stockOn the 21st of June, Henrik Dahlbom bought around 700 shares on-market at roughly kr155 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr513k. Insiders have collectively bought kr1.5m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Jun 13Chief Executive Officer recently bought kr513k worth of stockOn the 11th of June, Patrik Lundstrom bought around 3k shares on-market at roughly kr183 per share. This was the largest purchase by an insider in the last 3 months. This was Patrik's only on-market trade for the last 12 months.
Recent Insider Transactions • May 26Chief Financial Officer recently bought kr55k worth of stockOn the 19th of May, Hugo Petit bought around 240 shares on-market at roughly kr228 per share. This was the largest purchase by an insider in the last 3 months. This was Hugo's only on-market trade for the last 12 months.
Executive Departure • May 22Director has left the companyOn the 19th of May, Erik Karlsson's tenure in the role of Director ended. We don't have any record of a personal shareholding under Erik's name. A total of 3 executives have left over the last 12 months.
Executive Departure • May 22Director has left the companyOn the 19th of May, Henrik Norlin's tenure in the role of Director ended. We don't have any record of a personal shareholding under Henrik's name. A total of 3 executives have left over the last 12 months.
Recent Insider Transactions • May 21Interim Chief Financial Officer recently bought kr55k worth of stockOn the 19th of May, Hugo Petit bought around 240 shares on-market at roughly kr228 per share. This was the largest purchase by an insider in the last 3 months. This was Hugo's only on-market trade for the last 12 months.